We are raising our seed round.
The patient portal is in public beta and our first clinical trial begins in December 2026. This round builds the clinical core, certifies the hardware, and takes the portal from beta to scale.
Find the founder who covers your region.
We split coverage three ways and each founder answers their own mail. Whoever you write to is the person you will be dealing with, in your timezone, with no inbox in between.
What's already behind us
- 28
- UK pharmacy partnerships, CDSS pilot
- $134k
- UK government funding awarded
- $400k
- Angel investment, Hong Kong
- Dec 2026
- Clinical trial, EC Healthcare
- Feb 2027
- Clinical trial, Chinese Academy of Sciences
- 2
- Hardware partnerships, Chinese OEMs
One pipeline, sold to providers.
- 01 Live
Stage one is shipping
The patient portal is in public beta, open to anyone, and already building coded patient histories: the input everything downstream depends on.
- 02 Dec 2026
The clinical core goes to trial
Clinical trials are signed with EC Healthcare for December 2026 and the Chinese Academy of Sciences for February 2027.
- 03 2027
The package reaches clinics
With the hardware certified, providers buy the full pipeline: aggregation, reasoning and outputs, priced on the clinician time it saves.
Two routes to clinical revenue
Direct to digital services
API access to our CDSS engine for clinical service providers: ambient scribes, telehealth platforms, EMRs, triage tools and more.
Direct to service providers
Sold to hospitals, GP practices, pharmacies and other providers, priced on the clinician time our service saves.
Approval portability, not market size, decides where we go next.
One clinical deployment can feed several regulatory dossiers at once, so we sequence by how far an approval travels, not by how big a market looks.
Market rollout by wave
- Wellness launch: United Kingdom, United States, Canada, Australia. The patient portal goes direct-to-consumer across our first four markets.
- Clinical trials: China, Hong Kong. Auracare enters clinical trials with hospitals and institutions in Hong Kong and China.
- Product crossover: Singapore. The CDSS follows the portal into its wellness markets; the portal follows the CDSS into the CAS markets.
- Asia-Pacific: Taiwan, Malaysia, Thailand, Vietnam, Indonesia, Philippines, New Zealand. Approval portability carries both products across the region.
- Europe & Africa: Ireland, France, Germany, Spain, Italy, Nigeria, Kenya, Egypt, South Africa. Expansion into European and African markets.
- Rest of world: India, Brazil, Japan, Saudi Arabia. Everywhere else, more to come.
If you're new to Auracare
This page assumes you've seen the site. If you haven't, start with these.
FAQ
How much are you raising?
We share the target and terms directly rather than posting them here. Write to the founder for your region and we’ll walk you through the deck.
What’s live today, and what isn’t?
The ontology is live and explorable: 532,000 clinical concepts. The patient portal, the aggregation stage, is in public beta and open to anyone. The CDSS core is in development, with clinical trials signed with EC Healthcare (December 2026) and the Chinese Academy of Sciences (February 2027), and the full pipeline targeted for clinics in 2027.
Who’s already backing you?
A $400k angel investment from Hong Kong, around $400k in resources from the Founders Factory Healthcare accelerator, and $134k in UK government funding. We built 28 UK pharmacy partnerships and piloted the CDSS across them, and two Chinese OEM partnerships build our examination hardware.
How do you handle regulation?
The patient portal ships as a general-wellness product under the FD&C Act §520(o)(1)(B) exclusion, so it never diagnoses or treats. The Auracare CDSS is clinical decision support; its regulatory pathway is under active review.